A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Polk, Anne ^a   Vistisen, Kirsten ^a   Vaage Nilsen, Merete ^a   Nielsen, Dorte L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 fluorouracil; Cardiotoxicity; Pathophysiology; Systematic review

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CAPECITABINE; ENDOTHELIN 1; FLUOROURACIL; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC ANTIMETABOLITE;

ARTICLE; CARDIOTOXICITY; CELL DAMAGE; CORONARY ARTERY SPASM; CYTOLYSIS; DRUG SAFETY; ERYTHROCYTE METABOLISM; FIBRINOLYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; ANIMAL; DRUG EFFECTS; HEART;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; HEART; HUMANS;

EID: 84923025473     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-47     Document Type: Article

References (90)

1. Malet-Martino M, Jolimaitre P, Martino R: The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002, 2:267-310.
2. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL: Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013, 39:974-84.
3. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008, 134:75-82.
4. Meydan N, Kundak I, Yavuzsen T, Oztop I, Barutca S, Yilmaz U, Alakavuklar MN: Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005, 35:265-270.
5. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH: Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997, 17:729-736.
6. Ng M, Cunningham D, Norman AR: The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005, 41:1542-1546.
7. Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S, Turi ZG: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989, 7:509-514.
8. Jensen SA, Sorensen JB: 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012, 69:57-64.
9. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M: Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001, 23:1-8.
10. Kuzel T, Esparaz B, Green D, Kies M: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990, 65:885-889.
11. Lemaire L, Malet-Martino MC, De Forni M, Martino R, Lasserre B: Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992, 66:119-127.
12. Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980, 30:871-879.
13. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, Sakelariou D, Koufos C, Stamatelos G: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy-a survey of 427 patients. Med Sci Monit 2002, 8:I51-I57.
14. Moher D, Liberati A, TetzlaffJ, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
15. Kumar S, Gupta RK, Samal N: 5-fluorouracil induced cardiotoxicity in albino rats. Mater Med Pol 1995, 27:63-66.
16. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q: Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006, 25:305-309.
17. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M: 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 2012, 31:60.
18. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kacmaz M, Buyukkocak S, Ozturk HS: Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A 2000, 59:585-589.
19. Millart H, Kantelip JP, PlatonoffN, Descous I, Trenque T, Lamiable D, Choisy H: Increased iron content in rat myocardium after 5-fluorouracil chronic administration. Anticancer Res 1993, 13:779-783.
20. Millart H, Brabant L, Lorenzato M, Lamiable D, Albert O, Choisy H: The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res 1992, 12:571-576.
21. Satoh H, Hashimoto K: Effects of ftorafur and 5-fluorouracil on the canine sinoatrial node. Jpn J Pharmacol 1983, 33:357-362.
22. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M: The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995, 9:561-576.
23. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M: The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996, 10:805-818.
24. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M: Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 2003, 42:304-308.
25. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L: The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996, 7:731-737.
26. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993, 53:3028-3033.
27. Salepci T, Seker M, Uyarel H, Gumus M, Bilici A, Ustaalioglu BB, Ozturk A, Sonmez B, Orcun A, Ozates M, Irmak R, Yaylaci M: 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol 2010, 27:416-420.
28. SudhoffT, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W: 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004, 15:661-664.
29. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH: The antineoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol 1997, 99:426-432.
30. Spasojevic I, Maksimovic V, Zakrzewska J, Bacic G: Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning. J Chem Inf Model 2005, 45:1680-1685.
31. Spasojevic I, Zakrzewska J, Bacic GG: 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2metabolism. Ann N Y Acad Sci 2005, 1048:311-320.
32. Spasojevic I, Jelic S, Zakrzewska J, Bacic G: Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules 2009, 14:53-67.
33. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J: Changes of blood viscosity in patients treated with 5-fluorouracil-a link to cardiotoxicity? Acta Oncol 1995, 34:83-85.
34. Jensen SA, Hasbak P, Mortensen J, Sorensen JB: Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010, 28:5280-5286.
35. Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M: Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol 1992, 3:88.
36. Wenzel DG, Cosma GN: A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts. II. Doxorubicin, 5-fluorouracil and cyclophosphamide. Toxicology 1984, 33:117-128.
37. Tamatsu H, Nakazawa M, Imai S, Watari H: 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR). Jpn J Pharmacol 1984, 34:375-379.
38. Barnabe N, Zastre JA, Venkataram S, HasinoffBB: Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 2002, 33:266-275.
39. HasinoffBB, Patel D, Wu X: The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003, 35:1469-1479.
40. Hershko C, Link G, Tzahor M, Pinson A: The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993, 11:207-214.
41. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB: Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000, 275:13690-13698.
42. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, Chae SW: Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol 2005, 70:1066-1078.
43. Kwok JC, Richardson DR: Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 2002, 62:888-900.
44. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G: Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001, 61:8422-8428.
45. L'Ecuyer T, Horenstein MS, Thomas R, Vander HR: Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol Genet Metab 2001, 74:370-379.
46. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA: Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999, 84:257-265.
47. Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B: Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis 2013, 24:90-94.
48. Kim SM, Kwak CH, Lee B, Kim SB, Sir JJ, Cho WH, Choi SK: A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med 2012, 27:342-345.
49. Tsiamis E, Synetos A, Stefanadis C: Capecitabine may induce coronary artery vasospasm. Hellenic J Cardiol 2012, 53:320-323.
50. Shah NR, Shah A, Rather A: Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. J Oncol Pharm Pract 2012, 18:132-135.
51. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, Timour Q: 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 2011, 31:226.
52. Calik AN, Celiker E, Velibey Y, Cagdas M, Guzelburc O: Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. Am J Emerg Med 2012, 30:257-3.
53. Atar A, Korkmaz ME, Ozin B: Two cases of coronary vasospasm induced by 5-fluorouracil. Anadolu Kardiyol Derg 2010, 10:461-462.
54. Tajik R, Saadat H, Taherkhani M, Movahed MR: Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. Am Heart Hosp J 2010, 8:E111-E112.
55. Camaro C, Danse PW, Bosker HA: Acute chest pain in a patient treated with capecitabine. Neth Heart J 2009, 17:288-291.
56. Gianni M, Dentali F, Lonn E: 5 flourouracil-induced apical ballooning syndrome: a case report. Blood Coagul Fibrinolysis 2009, 20:306-308.
57. Yung LT, McCrea WA: Capecitabine induced acute coronary syndrome. BMJ Case Rep 2009, 2009.
58. Scott PA, Ferchow L, Hobson A, Curzen NP: Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. Emerg Med J 2008, 25:699-700.
59. Canale ML, Camerini A, Stroppa S, Porta RP, Caravelli P, Mariani M, Balbarini A, Ricci S: A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med (Hagerstown) 2006, 7:835-837.
60. Cardinale D, Colombo A, Colombo N: Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 2006, 22:251-253.
61. Mafrici A, Alberti A, Corrada E, Ferrari S, Marenna B: Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. Ital Heart J 2003, 4:895-899.
62. McGlinchey PG, Webb ST, Campbell NP: 5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. BMC Cardiovasc Disord 2001, 1:3.
63. Schnetzler B, Popova N, Collao LC, Sappino AP: Coronary spasm induced by capecitabine. Ann Oncol 2001, 12:723-724.
64. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401-410.
65. Okholm M, Iversen LH, Thorlacius-Ussing O, Ejlersen E, Boesby S: Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Dis Colon Rectum 1996, 39:1102-1106.
66. Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001, 31:388-394.
67. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C: Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004, 101:77-82.
68. Iversen LH, Okholm M, Thorlacius-Ussing O: Pre-and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease-a preliminary study. Thromb Haemost 1996, 76:523-528.
69. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G: Von Willebrand factor in colorectal cancer. Int J Colorectal Dis 2002, 17:42-45.
70. Rohsig LM, Damin DC, Stefani SD, Castro CG Jr, Roisenberg I, Schwartsmann G: von Willebrand factor antigen levels in plasma of patients with malignant breast disease. Braz J Med Biol Res 2001, 34:1125-1129.
71. Gil-Bazo I, Catalan G, V, Alonso GA, Rodriguez RJ, Paramo Fernandez JA, de la Camara GJ, Hernandez Lizoain JL, Garcia-Foncillas LJ: Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol 2005, 7:150-155.
72. Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen PM: Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005, 11:2166-2170.
73. Suzuki T, Nakanishi H, Hayashi A: Cardiac toxicity of 5-fluorouracil in rabbits. Jpn J Pharmacol 1977, 27 s:137. Ref Type: Abstract.
74. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T: Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013, 18:899-929.
75. Kehrer JP: The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000, 149:43-50.
76. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997, 43:1209-1214.
77. Li T, Danelisen I, Bello-Klein A, Singal PK: Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 2000, 46:523-530.
78. Siveski-Iliskovic N, Kaul N, Singal PK: Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994, 89:2829-2835.
79. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK: Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995, 11:551-554.
80. Alter P, Herzum M, SoufiM, Schaefer JR, Maisch B: Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006, 4:1-5.
81. Shoemaker LK, Arora U, Rocha Lima CM: 5-fluorouracil-induced coronary vasospasm. Cancer Control 2004, 11:46-49.
82. Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M: Coronary artery spasm induced by 5-fluorouracil. Eur Heart J 1991, 12:468-470.
83. Schwartz BG, Economides C, Mayeda GS, Burstein S, Kloner RA: The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. Int J Impot Res 2010, 22:77-90.
84. Nishizuka Y: Studies and perspectives of protein kinase C. Science 1986, 233:305-312.
85. Levin ER: Endothelins. N Engl J Med 1995, 333:356-363.
86. Khimji AK, Rockey DC: Endothelin-biology and disease. Cell Signal 2010, 22:1615-1625.
87. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH: The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 2001, 37:137-143.
88. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P: Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001, 104:1114-1118.
89. Arellano M, Malet-Martino M, Martino R, Gires P: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998, 77:79-86.
90. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME: 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994, 10:861-864.